Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible
A bispecific nanobody hitting primary endpoints in both asthma and CRSwNP phase 2 trials isn't just a pipeline win...
Moe Alsumidaie
AI Rewires Drug Discovery’s Economics, Infrastructure, and Biology Itself
At BIO-Europe Spring 2026, leaders from Eli Lilly, Schrödinger, Boltz, Bioptimus, and Sofinnova Partners convened to diagnose how foundation...
Global Biopharma Anchors Deals Amidst Macroeconomic Shifts and Neuroscience Renaissance
At the BIO-Europe Spring 2026 conference in Lisbon, a distinguished panel of business development and finance leaders convened to...
The $29 Billion March Wasn’t a Spike — It’s the Opening Bid for a Restructured Industry
Seven biopharma deals worth $29 billion closed in the final two weeks of March 2026. The street called it...
Challenging First-Line Therapy: How Dicot Pharma Is Rethinking Erectile Dysfunction from the Ground Up
A plant-derived compound with a novel mechanism, eight weeks of effect from three days of dosing, and a Phase...
Semaglutide’s Patent Cliff Isn’t a Generics Story — It’s a Market Architecture Story
As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...
Novo Nordisk’s Patent Cliff Isn’t Coming — It’s Already Here, and the Pricing Model Breaks on Impact
Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...
Lilly’s $6.3B Sleep Bet Isn’t About Sleep — It’s About Owning the Next Neuroscience Platform
Eli Lilly just paid $6.3 billion upfront for Centessa Pharmaceuticals and its sleep disorder pipeline. The price looks steep...
Biogen’s SPINRAZA High-Dose Approval Isn’t a Label Update — It’s a Lifecycle Defense Strategy in a Therapy Area That Is Running Out of Time
The FDA's approval of a high-dose nusinersen regimen looks like a routine label expansion. Read it as a commercial...
Novartis Is Buying the Next Generation of PI3Kα — Before the Current Generation Has Finished Paying Off
Novartis's acquisition of SNV4818 from Synnovation Therapeutics isn't a gap-fill — it's a calculated preemption. In a breast cancer...